Abstract
Fatty liver disease is one of most prevalent metabolic liver diseases, which includes alcoholic (ASH) and nonalcoholic steatohepatitis (NASH). Its initial stage is characterized by fat accumulation in the liver, that can progress to steatohepatitis, a stage of the disease in which steatosis is accompanied by inflammation, hepatocellular death, oxidative stress and fibrosis. Recent evidence in experimental models as well as in patients with steatohepatitis have uncovered a role for cholesterol and sphingolipids, particularly ceramide, in the transition from steatosis to steatohepatitis, insulin resistance and hence disease progression. Cholesterol accumulation and its trafficking to mitochondria sensitizes fatty liver to subsequent hits including inflammatory cytokines, such as TNF/Fas, in a pathway involving ceramide generation by acidic sphingomyelinase (ASMase). Thus, targeting both cholesterol and/or ASMase may represent a novel therapeutic approach of relevance in ASH and NASH, two of the most common forms of liver diseases worldwide.
Keywords: mitochondria, cholesterol, oxidative stress, steatohepatitis, cell death, sphingolipids, Nitric oxide, peroxynitrite, free radicals, antioxidants, nitrotyrosine, oxidation, nitration, fibrinogen
Current Pharmaceutical Design
Title: Metabolic Therapy: Lessons from Liver Diseases
Volume: 17 Issue: 35
Author(s): Carmen Garcia-Ruiz, Montserrat Mari, Anna Colell, Albert Morales and Jose C. Fernandez-Checa
Affiliation:
Keywords: mitochondria, cholesterol, oxidative stress, steatohepatitis, cell death, sphingolipids, Nitric oxide, peroxynitrite, free radicals, antioxidants, nitrotyrosine, oxidation, nitration, fibrinogen
Abstract: Fatty liver disease is one of most prevalent metabolic liver diseases, which includes alcoholic (ASH) and nonalcoholic steatohepatitis (NASH). Its initial stage is characterized by fat accumulation in the liver, that can progress to steatohepatitis, a stage of the disease in which steatosis is accompanied by inflammation, hepatocellular death, oxidative stress and fibrosis. Recent evidence in experimental models as well as in patients with steatohepatitis have uncovered a role for cholesterol and sphingolipids, particularly ceramide, in the transition from steatosis to steatohepatitis, insulin resistance and hence disease progression. Cholesterol accumulation and its trafficking to mitochondria sensitizes fatty liver to subsequent hits including inflammatory cytokines, such as TNF/Fas, in a pathway involving ceramide generation by acidic sphingomyelinase (ASMase). Thus, targeting both cholesterol and/or ASMase may represent a novel therapeutic approach of relevance in ASH and NASH, two of the most common forms of liver diseases worldwide.
Export Options
About this article
Cite this article as:
Garcia-Ruiz Carmen, Mari Montserrat, Colell Anna, Morales Albert and C. Fernandez-Checa Jose, Metabolic Therapy: Lessons from Liver Diseases, Current Pharmaceutical Design 2011; 17 (35) . https://dx.doi.org/10.2174/138161211798357700
DOI https://dx.doi.org/10.2174/138161211798357700 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of microRNA in Ischemic and Hemorrhagic Stroke
Current Drug Delivery Anti-Selectin Therapy for the Treatment of Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Gene Therapy for Heart Transplantation-Associated Acute Rejection, Ischemia / Reperfusion Injury and Coronary Arteriosclerosis
Current Gene Therapy A Journey into the World of Targeted Therapy: A Review of Gene Therapy, Stem Cell Therapy, and Cell Reprogramming in Cardiovascular Medicine
Recent Patents on Regenerative Medicine Serum Biochemical Markers of Brain Injury
Mini-Reviews in Medicinal Chemistry Targeting Platelet G-Protein Coupled Receptors (GPCRs): Looking Beyond Conventional GPCR Antagonism
Current Vascular Pharmacology Targeting Inhibition of COX-2: A Review of Patents, 2002 - 2006
Recent Patents on Inflammation & Allergy Drug Discovery Patent Selections
Recent Patents on Cardiovascular Drug Discovery The Cardiac Microvasculature in Hypertension, Cardiac Hypertrophy and Diastolic Heart Failure
Current Vascular Pharmacology A Concept of Homeostatic Inflammation Provided by Endogenous TLR4 Agonists that Function Before and After Danger Signal for Metastasis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Vascular Toxicity of Chemotherapeutic Agents
Current Vascular Pharmacology Phytochemistry and Pharmacological Update on Tetraterpenoids
The Natural Products Journal Periodontitis, Endothelial Dysfunction and Atherosclerosis
Vascular Disease Prevention (Discontinued) Repetitive Transient Phosphodiesterase-3 Inhibition Eliminates Non-ischemic Cardiac Remodeling and Failure
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Endothelial Endocytic Pathways: Gates for Vascular Drug Delivery
Current Vascular Pharmacology Arrhythmia Pharmacogenomics: Methodological Considerations
Current Pharmaceutical Design Low - Molecular Weight Heparins and Unfractionated Heparins during Primary Coronary Intervention
Cardiovascular & Hematological Agents in Medicinal Chemistry Surgical Ventricular Restoration: An Operation to Reverse Remodeling - Clinical Application (Part II) (Supplementry Table)
Current Cardiology Reviews Neuregulin1 as Novel Therapy for Heart Failure
Current Pharmaceutical Design Therapeutic Hypothermia for Cardiopulmonary Resuscitation: Why, When and How
Current Cardiology Reviews